TSN-1611 is under clinical development by Tyligand Biotechnology (Shanghai) and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II drugs for Colorectal Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TSN-1611’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TSN-1611 overview
TSN-1611 is under development for the treatment of pancreatic cancer, colorectal cancer, lung cancer, non-small cell lung cancer and other solid tumors. The drug candidate is nucleoside phosphohydrolase inhibitor targeting KRAS G12D. It is administered through oral route in the form of tablet.
Tyligand Biotechnology (Shanghai) overview
Tyligand Biotechnology (Shanghai) (Tyligand Biotechnology) is a drug research and development company. Tyligand Biotechnology is headquartered in Shanghai, China.
For a complete picture of TSN-1611’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
